Meet Our Team

Team and Resources

The team has extensive experience in technology development, commercialisation and company building. It includes two directors from Unilever, one of whom is R&D Director – Biotechnology & Biosourcing at Unilever and behind most of the patents for the technology. Our non-executive chair is Unilever Vice President Science and Technology, Unilever Homecare. In January 2022, Penrhos Bio appointed a CEO and Head of Business development as full-time employees. Accelerating the R&D cycle is supported by the Unilever R&D team, based at the MIF: one of the highest concentrations of materials science robotics in the world, a suite of advanced analytical equipment, a class II bioscience lab with state of the art automation of microbiology and world-leading anti-biofilm scientists. This expertise and resource provides an accelerated product development cycle with our commercial partners.

Core Team:

Dr Jonathan Hague

Chairman

Jon joined Penrhos bio from its inception. Jon is Vice President for Science and Technology Development in Unilever’s Global Homecare Business, a position he has held since January 2018. Prior to that Jon built and led Unilever’s Open Innovation capability, building partnerships with many of the world’s leading academic institutions and corporations. Jon also leads on the Unilever Green Future initiative, has a PhD in Materials Science from the University of Sheffield and almost 30 years of experience in Industrial R&D. Outside of Unilever duties, in addition to the role with Penrhos Bio, Jon is Chair of the Innovation Board for the Liverpool City Region, and is also Chair of the Innovation Committee of the UK Chemistry Council.

Dr Richard Hammond

Chief Executive Officer

Richard joined Penrhos Bio as a full-time employee in February 2022 having helped develop the original business model. As a veterinarian, Richard has a broad experience across commercial, academic, and veterinary clinical sectors for which he has been awarded a Fellowship of the Royal College of Veterinary Surgeons for meritorious contributions to the profession. He has worked as part of the commercial operation of a major pharmaceutical company, was part of the leadership team taking a new major Veterinary School (Nottingham) from concept to delivery and, as Head of School for Bristol University, delivered major organisational and strategic change with significant financial benefit. Notably, Richard grew the business of a small commercial veterinary enterprise from 60 staff and a breakeven position to over 280 staff and a turnover of circa £22m in the 7 years prior to joining Penrhos Bio. Richard is Professor Emeritus at the University of Bristol.

Dr Neil Parry

Technical Director

Neil is a biologist with a PhD in Industrial Biotechnology, specialising in protein engineering. Neil has worked within Unilever for over 25 years and has held a number of roles across the organisation, including within then Unilever antibody subsidiary, Unipath. Neil has held the role of Research Programme Director – Biotechnology & Biosourcing since 2012, leading the team developing new biotechnologies and green chemistries for Unilever’s product portfolio. Neil is a member of a number of advisory boards and is a non-exec Director on the National Biofilms Innovation Centre where he Chairs the Industry Advisory Board.

Dr Steve Howell

Commercial Director

Steve is a serial entrepreneur within the health care sector, having set up over a dozen companies who have raised over £100m of investment capital. He has been involved in M&A activities for both SMEs and large corporates, five on the sell-side and two on the buy-side. In 2006, he founded the life sciences investment and partnering business Innova Partnerships Ltd after a successful career in the diagnostics industry. He is currently visiting Professor of Commercial Innovation at Kings College London.

Paul Foulger

CFO

Paul is a qualified certified accountant and seasoned CFO with substantial strategic, entrepreneurial, and commercial experience at Board level within both start-up biotech companies as well as large corporates. He has been CFO at NovaBiotics Ltd, Venn Life Sciences plc, and Elsevier Science, amongst others. Paul has experience in managing a broad range of corporate transactions including lead roles in several IPOs on the AIM market, two management buy-outs, over £100m of fund-raising and a number of acquisitions both in Europe and the US. More recently he was Group CFO at EKF Diagnostics plc, the £200m+ market cap global point-of-care and central lab devices and tests medical manufacturer. He is currently CFO of GENinCode plc, the risk assessment specialist for the prediction of Cardiovascular disease, as well as CFO for PredictImmune Ltd, the personalised treatment provider for immune-mediated diseases.

Dr Andrew McNair

Operations Director

Andy has more than 25 years of experience working in the life sciences sector across a number of roles. A chemist, Andy has a PhD in hydrogel polymers and drug delivery. He has held senior management and directorial roles in a number of start-up and early-stage companies, as well as spending time as a commercialisation director in the university sector. In addition to the role with Penrhos Bio, Andy is Innova Partnerships Managing Director.

Dr Yvonne Davies

Head of Business Development

Yvonne joined Penrhos Bio full time in November 2021 as its first employee and since then has been leading the development of the company engagement and BD strategy. Yvonne has over 15 years of business development experience within fast growing start-ups, academic centres and established multinational organizations. She also has over 10 years senior management experience, including holding CEO positions within several technology start-ups. With highly developed commercialization skills, she is experienced in raising growth capital, licensing of intellectual property, knowledge transfer from external collaborators to internal R&D teams, leading contract negotiations and the identification and development of international strategic commercial partners. Yvonne also has product development experience in life sciences, physical sciences, paper industry and thin film industries.

Bacterial adhesion and biofilm formation on surfaces represent an increasingly serious societal problem from economic and health perspectives.  Hospital surfaces & equipment, medical devices, household surfaces & appliances as well as everyday items such as clothing and banknotes are constantly challenged by microbial contamination.  
 
Biofilm formation begins when free-floating micro-organisms such as bacteria or fungi come in contact with a surface and begin to adhere.  Following adherence, biofilms then start to develop and can grow into complex 3D structures through biological communication mechanisms.
 
Penrhos Bio is developing innovative naturally derived products that are active in solving bacterial and microbial problems in the marine, textile, paper, household cleaning and medical industries. 
 
Our vision is a world free of harmful biofilms.
Bacterial adhesion and biofilm formation on surfaces represent an increasingly serious societal problem from economic and health perspectives.  Hospital surfaces & equipment, medical devices, household surfaces & appliances as well as everyday items such as clothing and banknotes are constantly challenged by microbial contamination.  
 
Biofilm formation begins when free-floating micro-organisms such as bacteria or fungi come in contact with a surface and begin to adhere.  Following adherence, biofilms then start to develop and can grow into complex 3D structures through biological communication mechanisms.
 
Penrhos Bio is developing innovative naturally derived products that are active in solving bacterial and microbial problems in the marine, textile, paper, household cleaning and medical industries. 
 
Our vision is a world free of harmful biofilms.